BeStock  
Stocks › Biotechnology › GENB

Generate Biomedicines GENB

US equityMarket cap rank #2863Biotechnology
$13.91 +$0.22 (+1.61%)
Pre-market · Oct 6, 4:10 am ET · After hours $13.94 +0.20%
Open$13.71
Prev close$13.69
Day range$13.45 – $14.06
Volume1.12M
Market cap$1.79B
P/E (TTM)–
Dividend yield–

Cash flow

Line item 2025 ANNUAL 2024 ANNUAL
Net Preferred Stock Issuance $21.97M $96.32M
Proceeds from Stock Option Exercised $1.10M $1.13M
Net Other Financing Charges $13.15M $5.00M
Ending Cash Balance $126.04M $181.83M
Net Change in Cash -$55.79M -$84.15M
Beginning Cash Balance $181.83M $265.98M
Free Cash Flow -$204.13M -$121.20M
-Change in Receivables $308,000.00 -$213,000.00
Net Issuance Payments Of Debt -$8.16M -$11.12M
Net Cash Flow from Continuing Financing Activities $28.06M $91.33M
Financing Cash Flow $28.06M $91.33M
Operating Cash Flow -$200.62M -$117.75M
Net cash flow from continuing operations -$200.62M -$117.75M
Net Income from Continuing Operations -$222.97M -$181.38M
Gain/Loss from Continuing Operations $49,000.00 $144,000.00
Depreciation & Depletion & Amortization $13.18M $15.35M
Other Non-Cash Items $5.94M $6.01M
Change in Working Capital -$14.62M $28.12M
-Change in Prepaid Assets -$166,000.00 -$5.38M
-Change in Payables and Accrued Expense $15.24M $7.87M
Net Investment Purchase and Sale $120.28M -$54.29M
Net PPE Purchase and Sale -$3.51M -$3.44M
Net Cash Flow from Continuing Investing Activities $116.77M -$57.73M
Net cash flow from investing $116.77M -$57.73M
-Change In Other Working Capital -$31.89M $34.54M
-Change in Other Current Liabilities -$2.94M -$5.20M
-Change in Other Current Assets $4.84M -$3.50M

Discussion

No comments yet — be the first to weigh in on GENB.

Leave a comment

Scroll to Top